30 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).
Ontario Institute For Cancer Research
Structure-Based Design of¿-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
University of Michigan
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
University of North Carolina at Chapel Hill
Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening.
Chinese Academy of Sciences
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
TBA
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
UNC Eshelman School of Pharmacy
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Daiichi Sankyo Co., Ltd
Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.
Sun Yat-Sen University
Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors.
Sun Yat-Sen University
Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase.
University of California San Francisco
Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP.
Sun Yat-Sen University
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.
Sun Yat-Sen University
Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones as Potent NSD2 Inhibitors.
Shanghai Jiao Tong University
Computational methods-guided design of modulators targeting protein-protein interactions (PPIs).
Shanghai Jiao Tong University
Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5.
Sun Yat-Sen University
Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective.
China Pharmaceutical University
Small-Molecule Inhibitors of the MLL1 CXXC Domain, an Epigenetic Reader of DNA Methylation.
University of Virginia
Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
China Pharmaceutical University
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Chinese Academy of Sciences
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
China Pharmaceutical University
Engineering Fluorine into Verticillins (Epipolythiodioxopiperazine Alkaloids) via Precursor-Directed Biosynthesis.
University of North Carolina At Greensboro
Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.
China Pharmaceutical University
Methyllysine binding domains: Structural insight and small molecule probe development.
University of Connecticut
Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof
280 Bio